A new method of delivering cancer drugs that could cut down on chemotherapy's side effects and boost the strength of the tumor-fighting medicine has shown promise, US researchers said Wednesday.
Apr 4, 2012
0
0
(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), but does improve ...
Mar 27, 2012
0
0
The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with ...
Jun 6, 2011
0
0
Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such ...
May 16, 2011
0
0
Pooled data on two clinical trials demonstrate patients taking nivolumab realized a greater than five-fold increase in five-year overall survival rate compared with the chemotherapy docetaxel. The presentation was made today ...
Sep 10, 2019
0
0
Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase ...
Sep 11, 2017
0
0
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. (1)
Sep 8, 2017
0
4
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. ...
Aug 18, 2016
0
1
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast ...
Dec 3, 2015
0
0
